indomethacin has been researched along with Lupus Nephritis in 7 studies
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.
Lupus Nephritis: Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In a randomized crossover study, 8 patients with biopsy proven lupus nephritis were given 4 days' oral administration of DP-1904 (400 mg/day bid) or indomethacin (50 mg/day bid)." | 9.08 | Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis. ( Homma, M; Ichikawa, Y; Kameda, H; Tojo, T; Yoshida, T, 1996) |
| "The effects of indomethacin on urinary protein excretion, levels of serum albumin and renal function were studied prospectively in six patients with systemic lupus erythematosus (SLE) and refractory nephrotic syndrome due to lupus nephritis." | 9.07 | Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy. ( Cuellar, ML; Espinoza, LR; Jara, LJ; Martinez-Osuna, P; Seleznick, M; Silveira, LH, 1993) |
| " In a randomized crossover study, 8 patients with biopsy proven lupus nephritis were given 4 days' oral administration of DP-1904 (400 mg/day bid) or indomethacin (50 mg/day bid)." | 5.08 | Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis. ( Homma, M; Ichikawa, Y; Kameda, H; Tojo, T; Yoshida, T, 1996) |
| "The effects of indomethacin on urinary protein excretion, levels of serum albumin and renal function were studied prospectively in six patients with systemic lupus erythematosus (SLE) and refractory nephrotic syndrome due to lupus nephritis." | 5.07 | Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy. ( Cuellar, ML; Espinoza, LR; Jara, LJ; Martinez-Osuna, P; Seleznick, M; Silveira, LH, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Espinoza, LR | 1 |
| Jara, LJ | 1 |
| Martinez-Osuna, P | 1 |
| Silveira, LH | 1 |
| Cuellar, ML | 1 |
| Seleznick, M | 1 |
| Yoshida, T | 2 |
| Kameda, H | 2 |
| Ichikawa, Y | 1 |
| Tojo, T | 1 |
| Homma, M | 2 |
| Masashi, A | 1 |
| Ikeda, Y | 1 |
| Takahashi, H | 1 |
| Kimura, M | 1 |
| Hishida, A | 1 |
| Nishimura, M | 1 |
| Kiberd, BA | 1 |
| ter Borg, EJ | 1 |
| de Jong, PE | 1 |
| Meyer, S | 1 |
| van Rijswijk, MH | 1 |
| Kallenberg, CG | 1 |
| Pourrat, JP | 1 |
| Fournie, GJ | 1 |
| Fournie, B | 1 |
| Mignon-Conte, M | 1 |
| Conte, JJ | 1 |
3 trials available for indomethacin and Lupus Nephritis
| Article | Year |
|---|---|
Refractory nephrotic syndrome in lupus nephritis: favorable response to indomethacin therapy.
Topics: Adult; Creatinine; Female; Humans; Indomethacin; Kidney; Lupus Nephritis; Middle Aged; Nephrotic Syn | 1993 |
Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis.
Topics: Adult; Enzyme Inhibitors; Female; Humans; Imidazoles; Indomethacin; Kidney; Lupus Nephritis; Middle | 1996 |
Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Cross-Over Studies; Enzyme Inhibitors; Female; Humans; Imidazol | 1997 |
4 other studies available for indomethacin and Lupus Nephritis
| Article | Year |
|---|---|
Ureteral obstruction reverses glomerular proliferation in immune complex glomerulonephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Complement C3; Cyclooxygenase Inhibitors; Dinoprostone; Epopr | 1999 |
The functional and structural changes of the glomerulus throughout the course of murine lupus nephritis.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Body Weight; Carbazoles; Female; Glomerular Filtration Rate; | 1992 |
Indomethacin and ibuprofen-induced reversible acute renal failure in a patient with systemic lupus erythematosus.
Topics: Acute Kidney Injury; Female; Humans; Hydrochlorothiazide; Ibuprofen; Indomethacin; Lupus Nephritis; | 1987 |
[Treatment of lupus nephropathies without corticoids].
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Indomethaci | 1986 |